GlassScriptPhysician profile
Deborah Ann Johnoff
NPI 1902979172
$1,080.06
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $682 · 2022: $398.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $421.38 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $343.15 | 2021-2022 | |
| Genzyme Corporation | $113.31 | 2021-2022 | |
| Horizon Therapeutics Plc | $34.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.29 | 2021 | |
| Optinose US, INC. | $26.79 | 2021 | |
| Adma Biomanufacturing LLC | $17.96 | 2022 | |
| Uswm, LLC | $16.00 | 2021 | |
| Aimmune Therapeutics, INC. | $15.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.69 | 2022 | |
| Grifols USA, LLC | $13.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.84 | 2021 | |
| Pharming Healthcare, INC. | $11.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Johnoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.